Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review

Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment after liver transplantation. However, pegylate...

Descripción completa

Detalles Bibliográficos
Autores principales: Mucenic, Marcos, Brandão, Ajacio Bandeira de Melo, Marroni, Claudio Augusto, Fleck, Alfeu de Medeiros, Zanotelli, Maria Lucia, Leipnitz, Ian, Meine, Mário Henrique, Kiss, Guillermo, Martini, Juliano, Schlindwein, Eduardo Soares, Costabeber, Ane Micheli, Sacco, Fernanda Karlinsky Rodrigues, Rossato, Giovana, Cantisani, Guido Pio Cracco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto de Medicina Tropical 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376924/
https://www.ncbi.nlm.nih.gov/pubmed/30785566
http://dx.doi.org/10.1590/S1678-9946201961012
Descripción
Sumario:Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment after liver transplantation. However, pegylated interferon may still be required for genotype 3 non-responders. We treated a liver graft recipient with grade 1 fibrosis in the biopsy with daclatasvir and sofosbuvir for 12 weeks. He did not respond and progressed to grade 3 fibrosis. Lacking other options, we obtained a sustained virological response with pegylated interferon, ribavirin and sofosbuvir for 12 weeks. The combination of pegylated interferon, ribavirin and sofosbuvir is a viable option after the failure of direct acting antivirals in economically disadvantaged countries.

Ejemplares similares